SCHEMBL5689609

SCHEMBL5689609

O=C(O)Cc1ccc(OCC2CCN(C(=O)Oc3ccc(N4C(=O)C5CCCCC5C4=O)cn3)CC2)cc1

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
LIPE Q05469 2/20 0.39
GPR119 Q8TDV5 5/20 0.37
CYP4F2 P78329 2/20 0.36
CYP4A11 Q02928 2/20 0.36
ALDH1A1 P00352 3/20 0.36
GAA P10253 1/20 0.36
HPGD P15428 1/20 0.36
ACACB O00763 1/20 0.35
POLB P06746 2/20 0.35
LMNA P02545 1/20 0.35
MAPT P10636 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
GRM2 Q14416 2/20 0.35
GRIN2B Q13224 1/20 0.35
MGLL Q99685 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5690083 0.90 KMT2A (0.47) KMT2AL3MBTL1LIPEGPR119ALDH1A1
SCHEMBL5687328 0.89 KMT2A (0.42) KMT2AL3MBTL1LIPEGPR119CYP4F2
SCHEMBL5931636 0.84 LIPE (0.38) LIPEGPR119CYP4F2CYP4A11ACACB
SCHEMBL5688267 0.84 LIPE (0.45) KMT2AL3MBTL1LIPEGPR119CYP4F2
SCHEMBL5688056 0.84 LIPE (0.45) KMT2AL3MBTL1LIPECYP4F2CYP4A11
SCHEMBL5904319 0.82 KMT2A (0.41) KMT2AL3MBTL1GPR119ALDH1A1GAA
SCHEMBL5690688 0.78 KMT2A (0.37) KMT2AL3MBTL1LIPEGPR119ALDH1A1
SCHEMBL5690596 0.78 SRD5A1 (0.45) KMT2AL3MBTL1GPR119ALDH1A1GAA
SCHEMBL5689797 0.77 ALDH1A1 (0.36) KMT2AL3MBTL1LIPEGPR119CYP4F2
SCHEMBL5687711 0.77 DGAT1 (0.52) KMT2ALIPESMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060160851-A1 Substituted piperidine carbamates NOVO NORDISK A/S (DK) 2006-07-20 US claimed
EP-1636207-A1 SUBSTITUTED PIPERIDINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2006-03-22 EP claimed
WO-2004111032-A1 SUBSTITUTED PIPERIDINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-12-23 WO claimed
EP-1636207-A1 SUBSTITUTED PIPERIDINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2006-03-22 EP disclosed
WO-2004111032-A1 SUBSTITUTED PIPERIDINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060160851-A1 Substituted piperidine carbamates LIPE, PNLIP, LIPC KMT2A 1520/4885L3MBTL1 2710/4885LIPE 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.